Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaArsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathwayInhibition of histone deacetylases in cancer therapy: lessons from leukaemiaAcute promyelocytic leukemia: where did we start, where are we now, and the futureControversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesHow animal models of leukaemias have already benefited patientsVitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteinsTargeting of leukemia-initiating cells in acute promyelocytic leukemiaPhenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesisPioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.Disruption of histone modification and CARM1 recruitment by arsenic represses transcription at glucocorticoid receptor-regulated promoters.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYCCuring all patients with acute promyelocytic leukemia: are we there yet?Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapseEndoplasmic reticulum calcium pumps and cancer cell differentiation.Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule.Pin1-Targeted Therapy for Systemic Lupus ErythematosusValproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells.Leukaemogenesis: more than mutant genesDynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia.PML-mediated signaling and its role in cancer stem cells.MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia.Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemiaOxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.Personalized medicine and cancer.Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsDeferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.Effector caspases and leukemiaCombining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomasAutophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein.Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaReactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated autophagyPML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway.The APL paradigm and the "co-clinical trial" project.
P2860
Q24605527-BBE49380-C908-428A-B9BC-DC438196BA32Q24623800-7855F886-5409-44E9-A084-6E536B5BF900Q26767024-EB98EB53-4A0D-4849-9E2C-C317C4154018Q26830385-C21E3961-2B38-4AE9-B520-B5593CF4C03DQ26852683-D1CFE2DC-A27F-48BD-A547-F3B2A176BF87Q26853348-D9ABAF92-1B92-4DCA-A01D-58F9DDF4DECAQ26997702-B9FC93E7-497C-492E-BC7A-384B45D4B892Q28081177-1220466D-0C7A-42C1-87A2-09919829A2C2Q28083807-827CCD9B-CAEC-43F5-BAB2-C00080BF4EBFQ28833723-33FBDF51-E33E-4167-822D-1198E4600B3FQ30490577-73DB4000-1A0D-4441-8359-96185AE2CEB7Q33496730-3DBC82A1-28E8-4F62-9A4C-85E118DBDD54Q33551142-D1C8638E-3673-4219-A1B5-92CA9A55B346Q33560429-ADC2BB57-92BE-47FC-ACB6-F1E5C9DA4B96Q33613426-3AA20516-5A6B-42A9-A98E-A957CAE2DC79Q33622409-C8525181-6D8F-4B7B-97F3-6C9DC6A94294Q33623363-C9057945-6237-47CA-ADB3-5BDF92B69D52Q33649613-6CC88D0D-89AD-4B92-8E88-E0A384A0D596Q33795018-C743A7A3-EE39-40E3-A4F7-F7475A191AC6Q33840263-DBF3D382-1A06-4E3B-9F5F-BFCF331B4AE0Q33859906-2C87EB34-82E3-4180-B91A-570BE59E4632Q34254302-02177D99-DB15-4747-B3F8-BAA5EE63E7E9Q34270770-938B1644-8B94-40F4-90AC-92E5245DA829Q34275371-FCAEA822-18E3-4FDC-AC10-3A1B65A89FBCQ34287738-66DD4909-DDDE-4B62-9633-01C54FC937B7Q34337626-2D384E03-F5E2-43C1-B65E-61E47AF33E0CQ34344666-47688C06-4ADB-48FB-A4BF-224CCCC2305CQ34420787-3F016459-61CD-4FB1-A75C-CC7EED5C59DBQ34509473-23A73AE6-0FEA-4183-BF37-B874003A6A41Q34608577-46916375-F23F-46F4-A5D2-00A83F68423EQ34658892-3389B9A9-6B9A-40C2-AF35-A227267156D0Q34804866-16031012-CE90-4995-95EC-751D8D86E311Q35013020-0609E0FD-D207-4C48-BB5A-4ABC829F18A8Q35018971-DF45CB4F-E413-4559-8A4D-B738A22B9562Q35046691-A3D9D20E-663C-4F83-8FB4-32F44A5E56F9Q35079502-8C59CDED-7EAB-4A75-AACB-090E7B5080C4Q35085867-C188F5EB-0160-490F-8611-337772801716Q35402749-1343A932-A2E2-454F-B8BA-CEF7B7C5A55EQ35534091-EF668457-9EC2-46A9-A41F-5F7D25538348Q35568084-5A6C3199-A24A-41E0-8310-8C7F8817FA43
P2860
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
description
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im Dezember 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/12/01)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/12/01)
@nl
наукова стаття, опублікована в грудні 2008
@uk
مقالة علمية (نشرت في ديسمبر 2008)
@ar
name
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@ast
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@en
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@nl
type
label
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@ast
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@en
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@nl
prefLabel
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@ast
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@en
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@nl
P2093
P50
P3181
P356
P1433
P1476
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
@en
P2093
Bernard Gourmel
Caroline Berthier
Cécile Rochette-Egly
Dominique Vitoux
Hassan Soilihi
Laurent Peres
Macarena Robledo-Sarmiento
Omar Ferhi
Philippe Rousselot
P2888
P304
P3181
P356
10.1038/NM.1891
P407
P577
2008-12-01T00:00:00Z